Imaging · Contrast AgentRegulatory Approvalregulatorymid-term

FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 6:04:50 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Gadobutrol by Viwit Pharm introduces a new competitor in the contrast agent market, which could disrupt existing market dynamics. Pharma strategy teams need to evaluate the implications for pricing and market share of current products in this therapeutic area. Regulatory context from FDA (FDA AP — GADOBUTROL (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing contrast agents. The strongest clinical anchor is Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT (ClinicalTrials.gov), moderate corpus alignment. In Imaging · Contrast Agent, 6 regulatory and 2 competitive items passed relevance filtering for Gadobutrol.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This approval allows Viwit Pharm to enter the market for Gadobutrol, potentially increasing competition in the contrast agent segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GADOBUTROL (ORIG) (FDA). Entity match (gadobutrol); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval signifies compliance with FDA standards, but ongoing monitoring of market entry and performance is necessary to assess long-term regulatory implications.

Key Risks

Elevated medium regulatory exposure for Gadobutrol could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study) could weigh on Gadobutrol through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Viwit Pharm into the contrast agent market may lead to increased competition, potentially affecting pricing strategies and market share for existing players.
Upside for Gadobutrol may improve if Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing contrast agents.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and initial sales performance of Gadobutrol by Viwit Pharm.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (SUPPL)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (SUPPL)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — NDA219627
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Contrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gadobutrol

Commercial impact

medium

The entry of Viwit Pharm into the contrast agent market may lead to increased competition, potentially affecting pricing strategies and market share for existing players.

Regulatory impact

medium

The approval signifies compliance with FDA standards, but ongoing monitoring of market entry and performance is necessary to assess long-term regulatory implications.

What to watch

Monitor market entry timelines and initial sales performance of Gadobutrol by Viwit Pharm.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.